With more than two decades on the faculty of USC Keck School of Medicine, Dr. Gordon advanced research and mentored the next generation of physician-scientists. She has guided groundbreaking research programs in red cell disorders and hemophilia, advancing care for children and adults with complex blood conditions.

Her expertise in biotechnology and gene therapy has led to pioneering innovations, including approval for the world’s first targeted genetic medicine for cancer. She played a central role in securing FDA orphan drug approvals, fast-track designations, and accelerated approval pathways that have brought novel therapies to patients faster.

At the Cancer Center of Southern California, Dr. Gordon continues to drive progress in immunological and biological cancer therapies, ensuring cutting-edge science is translated into safe, effective treatments for patients with rare and difficult-to-treat cancers.

Dr. Gordon is a pioneer in translational biomedical research whose work has reshaped the field of targeted cancer therapy. She is co-inventor of over 150 patents, including the first targeted gene delivery system for cancer approved in the United States, Europe, and the Philippines. With over 100 peer-reviewed publications, her research continues to bridge laboratory innovation with real-world patient care.

She also helped establish the nation’s first Academic Vector Production Unit at USC’s Norris Comprehensive Cancer Center, where she guided clinical protocols in targeted gene therapy for eight years. Her leadership in this area laid the foundation for bringing novel genetic medicines from the lab to patients in need.